ClinicaliQ Trial Snapshot
- A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma — Recruiting • Cardiology / Cardiovascular • NCT05160584.
- What is being tested: Real-world effectiveness, safety, and patient-reported outcomes of standard-of-care antimyeloma treatments in relapsed/refractory multiple myeloma patients over 24 months, reflecting actual clinical practice rather than controlled trial conditions.
- Patient eligibility overview: Adults with relapsed and/or refractory multiple myeloma who have received prior treatment, assessed in routine NHS or comparable healthcare settings during standard clinical management.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
Eligibility Snapshot
- : * For Period 1 and 2: Have a documented diagnosis of multiple myeloma according to International myeloma working group (IMWG) diagnostic criteria. For Period 3: Start of talquetamab for the treatment of a documented diagnosis of relapsed and/or refractory multiple myeloma (RRMM) according to IMWG diagnostic criteria and the approved indication. The decision to start talquetamab must be made independently of the decision to participate in the study, with the start of treatment occurring up to 28 days following the start of screening or having occurred up to 21 days before the informed consent form (ICF) date * For Period 1 and 2: Have an Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1. For Period 3: Have ECOG performance status of 0,1 or 2 * For Period 1,2 and 3: Must not be pregnant or must not plan to become pregnant within the study period * For Period 1,2 and 3: Participants must sign an ICF indicating that he or she understands the purpose and observational nature of the study and is willing to participate. Consent is to be obtained prior to the initiation of any study-related data collection * For Period 1 and…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.